News

“This is an important day, as the initiation and dosing of the first patients in the ANCHOR phase 1 clinical study marks the first time that patients have

The randomised, double-blind, exploratory phase I trial A has been designed to evaluate the pharmacokinetic profile, safety and tolerability of a continuous daily dosing regimen of Ivermectin in

Koligo is involved in the development of personalised cell therapies using the cells of the patient. The company already commercialised its first commercial product Kyslecel for the treatment

A team from ViiV Healthcare will work with clinical staff at 18 diverse practice sites across different healthcare systems in France, Spain, Belgium, Germany, and the Netherlands during

AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. AVROBIO recently dosed the first

Xeljanz, claimed to be the first and only Janus kinase (JAK) inhibitor approved in the US to treat pcJIA, is available in two formulations such as a tablet

The company’s investigational new drug application (IND) for the clinical trial will be on partial clinical hold until the regulator receives satisfying answers for the questions. The partial

RA is a chronic, progressive, systemic, inflammatory disease that can lead to significant and irreversible joint destruction, pain and functional impairment.2 Almost 3 million people in Europe are

ELEVATE UC 12 is the second of two pivotal trials within the Phase 3 ELEVATE UC registrational program to assess the safety and efficacy of etrasimod 2 mg.